Soft Touch Pharmaceutical India Profile
Key Indicators
- Authorised Capital ₹ 2.15 Cr
as on 29-11-2024
- Paid Up Capital ₹ 1.31 Cr
as on 29-11-2024
- Company Age 21 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 Cr
as on 29-11-2024
- Revenue 156.78%
(FY 2024)
- Profit 108.28%
(FY 2024)
- Ebitda 1068.18%
(FY 2024)
- Net Worth 17.44%
(FY 2024)
- Total Assets 45.36%
(FY 2024)
About Soft Touch Pharmaceutical India
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.15 Cr and a paid-up capital of Rs 1.31 Cr.
The company currently has active open charges totaling ₹5.00 Cr.
Ram Garg, Atul Garg, and Shashi Garg serve as directors at the Company.
- CIN/LLPIN
U24232HP2003PLC026293
- Company No.
026293
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
19 Aug 2003
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Company Details
- Location
Solan, Himachal Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Soft Touch Pharmaceutical India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Atul Garg  | Director | 19-Aug-2003 | Current |
| Ram Garg | Director | 19-Aug-2005 | Current |
| Shashi Garg | Director | 02-Nov-2023 | Current |
Financial Performance of Soft Touch Pharmaceutical India.
Soft Touch Pharmaceutical India Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 156.78% increase. The company also saw a substantial improvement in profitability, with a 108.28% increase in profit. The company's net worth Soared by an impressive increase of 17.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Soft Touch Pharmaceutical India?
In 2024, Soft Touch Pharmaceutical India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Yester Pharma Private LimitedActive 4 years 7 monthsRam Garg, Atul Garg and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 14 Oct 2020 | ₹5.00 Cr | Open |
How Many Employees Work at Soft Touch Pharmaceutical India?
Soft Touch Pharmaceutical India has a workforce of 29 employees as of Nov 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Soft Touch Pharmaceutical India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Soft Touch Pharmaceutical India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
